Revolution Medicines, Inc. (RVMD)
Biological Products, (No Diagnostic Substances) · market cap $41.1B · as of 2026-11-20
Research and calibrated estimates, not financial advice — verify before acting.
- 2027-05-31 (est.)Phase 2 · RMC-6236imp 7/10
- 2027-06-15 (est.)Phase 2 · RMC-6236imp 7/10
| Asset | Phase | Indication |
|---|---|---|
| daraxonrasib | Phase 3 | NSCLC (Non-small Cell Lung Cancer) |
| RMC-4630 | Phase 2 | Non-Small Cell Lung Cancer |
| RMC-6236 | Phase 3 | Colorectal Cancer |
| RMC-6291 | Phase 2 | Non-Small Cell Lung Cancer, NSCLC |
| Cobimetinib | Phase 2 | Solid Tumor |
| zoldonrasib | Phase 3 | Pancreatic Cancer |
| pemetrexed + cisplatin/carboplatin | Phase 3 | NSCLC |
| Liposomal irinotecan | Phase 3 | Pancreatic Cancer |
| mFOLFOX6 regimen | Phase 2 | Colorectal Cancer |
| Leucovorin (Calcium Folinate) | Phase 3 | Pancreatic Cancer |
| Ivonescimab | Phase 2 | Advanced Solid Tumors |
| Elironrasib | Phase 2 | Advanced Solid Tumors |
| cetuximab (Cohort C2 Only) | Phase 2 | Advanced Solid Tumors |
| Daraxonrasib (Cohort B1 only) | Phase 2 | Advanced Solid Tumors |
| TNG462 | Phase 2 | PDAC |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Phase 2 | Advanced Solid Tumors |
| Gemcitabine (GEM) | Phase 3 | Pancreatic Cancer |
| mFOLFIRINOX regimen | Phase 2 | Colorectal Cancer |
| RMC-9805 | Phase 2 | Colorectal Cancer |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Phase 2 | Advanced Solid Tumors |
Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for RVMD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
